Home › Compare › MANVF vs ABBV
MANVF yields 1333.33% · ABBV yields 3.06%● Live data
📍 MANVF pulled ahead of the other in Year 1
Combined, MANVF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MANVF + ABBV for your $10,000?
Manning Ventures Inc. engages in the sourcing and exploration of mineral properties in Canada. It primarily explores for gold, silver, lead, iron ore, zinc, cobalt, uranium, rare earth, and copper deposits. The company holds interest in the Flint Lake gold project, which includes 4 separate unpatented claims covering an area of approximately 1,712 hectares located in Kenora town, northwestern Ontario. It also holds interest in the Lac Simone property, which consists of 63 mineral claims covering an area of approximately 3,287.4 hectares; and the Hope Lake property which includes 68 mineral claims covering an area of approximately 3,584.1 hectares. In addition, the has an option to acquire a 100% interest in the Broken Lake, Heart Lake, and Hydro properties that consist of 180 mineral claims covering an area of 9,501 hectares located in the Province of Quebec; and the Bounty lithium project comprises 144 mineral claims totaling 7,544 hectares. Further, it holds interest in Butterfly Pond property covering an area of 425 hectares, Mount Hogan property which covers an area of 250 hectares, Red Indian Lake property covering an area of 9,300 hectares, and Little Sheep Brook property covering an area of 700 hectares located in Newfoundland, Canada. Manning Ventures Inc. was incorporated in 2018 and is based in Vancouver, Canada.
Full MANVF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.